Neutralizing antibodies to human endothelin
AssigneeFather Flanagan's Boys' Home doing business as Boys Town National Research Hospital
InventorDominic Cosgrove
Life of this patent
Estimating the term…
Abstract
This application provides antibodies and functional equivalents thereof which are capable of neutralizing endothelin-1, as well as their use in the treatment of disease conditions associated with endothelin-1 activation, such as Alport syndrome.
Claims37
(canceled)
An antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC® Patent Deposit Designation PTA-125818.
3-4. (canceled)
An antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC® Patent Deposit Designation PTA-125818.
6-7. (canceled)
The monoclonal antibody produced by hybridoma cell line Nab #7 3G 9A4 deposited under ATCC® Patent Deposit Designation PTA-125818, or an antigen binding fragment thereof.
(canceled)
15-16. (canceled)
18-19. (canceled)
The Nab #7 3G 9A4 hybridoma cell line as deposited under ATCC® Patent Deposit Designation PTA-125818, and progeny thereof.
(canceled)
25-27. (canceled)
Dependencies are inferred from the claim text.